Trade HALO

Halozyme Therapeutics Inc

00:00:00

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Name	Sell	1D Chg
SMTC Semtech Corp	42.38	6.357%
FDX Fedex	263.90	0.501%
NIO NIO Limited	6.260	1.294%
DOYU DouYu International Holdings Ltd - ADR	9.408	0.899%
DVMT Dell Technologies Inc	124.41	0.817%
TSLA Tesla Motors	240.96	-0.339%

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage.

The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Account Base Currency

Instrument

Volume in Lots (Contract Size 100,000)

Price

Long Buy Short Sell

Set Stop Loss Amount :

Set Profit Amount :

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss.

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value.

The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate